OPUS GENETICS INC(IRD)

3.58-0.24-6.41%

CommunityCommunity
NewsNews
ProfileProfile
AnnouncementsAnnouncements

- Opus Genetics is Maintained at Buy by Chardan Capital
  Dow Jones · 10-22 20:57
  Opus Genetics is Maintained at Buy by Chardan Capital
- Opus Genetics Chief Scientific and Development Officer Ashwath Jayagopal Steps Down
  Reuters · 10-22 04:16
  Opus Genetics Chief Scientific and Development Officer Ashwath Jayagopal Steps Down
- Opus Genetics Gets FDA Clearance to Test OPGx-RDH12 Gene Therapy
  Reuters · 10-21 19:06
  Opus Genetics Gets FDA Clearance to Test OPGx-RDH12 Gene Therapy
- Opus Genetics Announces FDA Clearance of Ind Application for Opgx-Rdh12 Gene Therapy for Inherited Childhood Blindness
  THOMSON REUTERS · 10-21 19:00
  Opus Genetics Announces FDA Clearance of Ind Application for Opgx-Rdh12 Gene Therapy for Inherited Childhood Blindness
- Opus Genetics - to Initiate Phase 1/2 Trial of Opgx-Rdh12 This Quarter
  THOMSON REUTERS · 10-21 19:00
  Opus Genetics - to Initiate Phase 1/2 Trial of Opgx-Rdh12 This Quarter
- Opus Genetics Wins FDA Approval for Ryzumvi to Treat Presbyopia in Adults
  Reuters · 10-17
  Opus Genetics Wins FDA Approval for Ryzumvi to Treat Presbyopia in Adults
- Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
  THOMSON REUTERS · 10-17
  Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
- Opus Genetics' OPGx-BEST1 Improves Retinal Sensitivity in 75% of Evaluable Patients in Early-Stage Trial
  Reuters · 10-16
  Opus Genetics' OPGx-BEST1 Improves Retinal Sensitivity in 75% of Evaluable Patients in Early-Stage Trial
- Opus Genetics Presents at Chardan Annual Healthcare Conference
  Reuters · 10-13
  Opus Genetics Presents at Chardan Annual Healthcare Conference
- US Research Roundup-Affiliated Managers Group, Goldman Sachs, Vaxcyte
  Reuters · 10-06
  US Research Roundup-Affiliated Managers Group, Goldman Sachs, Vaxcyte
- Opus Genetics Inc : Jonestrading Raises Target Price to $17 from $10
  THOMSON REUTERS · 10-06
  Opus Genetics Inc : Jonestrading Raises Target Price to $17 from $10
- Foundation Fighting Blindness Retinal Degeneration Fund Disposes of Opus Genetics Common Shares Worth $2,756,020.80
  Reuters · 10-03
  Foundation Fighting Blindness Retinal Degeneration Fund Disposes of Opus Genetics Common Shares Worth $2,756,020.80
- Opus Genetics Price Target Maintained with a $16.00/Share by Chardan Capital
  Dow Jones · 10-02
  Opus Genetics Price Target Maintained with a $16.00/Share by Chardan Capital
- LifeSci Capital Remains a Buy on Opus Genetics (IRD)
  TIPRANKS · 09-13
  LifeSci Capital Remains a Buy on Opus Genetics (IRD)
- Opus Genetics Posts OPGx-BEST1 Phase 1/2 Low-Dose Cohort Presentation
  Reuters · 09-11
  Opus Genetics Posts OPGx-BEST1 Phase 1/2 Low-Dose Cohort Presentation
- Health Rounds: Experimental Eye Drops Ease Night Vision Problems for Drivers
  Reuters · 09-11
  Health Rounds: Experimental Eye Drops Ease Night Vision Problems for Drivers
- Thomas Shrader Reiterates Buy on IRD, Maintains $12 Price Target Amid Encouraging Clinical and Regulatory Progress
  TIPRANKS · 09-10
  Thomas Shrader Reiterates Buy on IRD, Maintains $12 Price Target Amid Encouraging Clinical and Regulatory Progress
- Opus Genetics up over 32%, on Track for Largest Percent Increase Since February 2020
  Dow Jones · 09-10
  Opus Genetics up over 32%, on Track for Largest Percent Increase Since February 2020
- Opus Genetics Reach 52-Week High on Clinical Trial, FDA Progress
  Dow Jones · 09-10
  Opus Genetics Reach 52-Week High on Clinical Trial, FDA Progress
- Top Midday Gainers
  MT Newswires Live · 09-10
  Top Midday Gainers
Company Profile
Company Name
OPUS GENETICS INC
Market
NASDAQ
Establishment Date
- -
Employees
- -
Office Location
- -
Website
http://www.ocuphire.com;ir.opusgtx.com;www.opusgtx.com
Zip Code
- -
Phone
- -
Fax
- -
Introduction
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
- 10-15
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 09-11
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 09-09
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 09-04
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 08-14
  Beneficial Ownership Change
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
  Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
- 08-13
  Correspondence
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 08-06
  Quarterly Report
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
  Form 10-Q - Quarterly report [Sections 13 or 15(d)]
- 08-06
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report
- 07-24
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 07-24
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 07-24
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 07-24
  Proposed Sale Of Securities
  Form 144 - Report of proposed sale of securities
  Form 144 - Report of proposed sale of securities
- 06-16
  Major Issues Report
  Form 8-K - Current report
  Form 8-K - Current report

1D
5D
Day
Week
Month

Loading ...

High

3.80

Open

3.79

Volume%

0.89

Low

3.56

3.82

T/O Rate

0.34%

To The Moon

OPUS GENETICS INC(IRD)

Company Profile

Most Discussed